Innovating Works

SAPHIR

Financiado
Strengthening Animal Production and Health through the Immune Response
SAPHIR aims to develop vaccine strategies effective against endemic pathogens responsible for high economic losses in livestock in order to strengthen the profitability of food animal systems, improve animal welfare and reduce xen... SAPHIR aims to develop vaccine strategies effective against endemic pathogens responsible for high economic losses in livestock in order to strengthen the profitability of food animal systems, improve animal welfare and reduce xenobiotic usage in farming with a One Health perspective. SAPHIR will bring novel vaccine strategies to the market i) at short term, with several promising vaccines brought to demonstration (RTL6), ii) at long term, with cutting edge strategies brought at proof of concept (RTL3) and iii) in line with socio-economic requirements. SAPHIR has selected two representative pathogens of pigs (Porcine Reproductive and Respiratory Syndrome Virus and Mycoplasma hyopneumoniae), chickens (Eimeria and Clostridium perfringens) and cattle (Bovine Respiratory Syncytial Virus, Mycoplasma bovis) to develop generic vaccine approaches applicable to other pathogens. SAPHIR will issue i) knowledge of immune mechanisms of protection, ii) affordable, safe and multivalent vaccines with DIVA properties, iii) efficient adjuvants targeting dendritic cells, optimal formulations, new mucosal and skin delivery systems, a new generation of DNA vectors and viral replicon platforms for fostering an earlier and longer duration of immunity including the perinatal period, and iv) basal biomarkers of individual immuno-competence for future breeding strategies. The SAPHIR dissemination and training programme includes creation of an integrated health management website, launch of a Global Alliance for Veterinary Vaccines and organization of workshops directed at food animal system stakeholders. This will ensure optimal research translation of SAPHIR outputs to market and field applications. SAPHIR brings together interdisciplinary expertise from fourteen academic institutes including a Chinese partner, five SMEs and two pharmaceutical companies. ver más
28/02/2019
INRAE
11M€
Duración del proyecto: 48 meses Fecha Inicio: 2015-02-18
Fecha Fin: 2019-02-28

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-02-28
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
SFS-01b-2014: Tackling losses from terrestrial animal diseases
Cerrada hace 10 años
Presupuesto El presupuesto total del proyecto asciende a 11M€
Líder del proyecto
INSTITUT NATIONAL DE RECHERCHE POUR LAGRICULT... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5